Expression of PPARgamma and beta/delta in human primary osteoblastic cells: influence of polyunsaturated fatty acids.
As previously reported, the age-related association between bone loss and increased marrow adipose volume may involve inhibitory effects of polyunsaturated fatty acids (PUFAs) potentially released by medullary adipocytes on osteoblastic proliferation and cell cycle progression. Because PUFAs have been reported to activate peroxisome proliferator-activated receptors (PPARs), we investigated the expression of these nuclear receptors in human primary osteoblastic (hOB) cells and examined the effects of natural PPAR ligands on hOB cell proliferation. We demonstrated basic expressions of PPARgamma and PPARbeta/delta in hOB cells at the protein level. As already shown for PUFAs, a short-term treatment with 15deoxy-Delta(12,14) -prostaglandin J2 (15dPGJ2) or prostacyclin (PGI2), which are specific ligands for PPARgamma and PPARbeta/delta, respectively, also significantly inhibited hOB cell proliferation. Given that the cell cycle withdrawal resulting from PPARgamma activation was often associated with the induction of cell differentiation, long-term effects of PUFAs and 15dPGJ2 were also assessed on the expression levels of transcription factors. PUFAs and 15dPGJ2 enhanced the expression of PPARgamma in hOB cells. It is of interest to note that PPARgamma protein level was dose-dependently increased, whereas that of Cbfal was decreased by a fatty acid-rich serum. In conclusion, this study shows that PPARgamma and beta/delta are expressed by hOB cells. The results further suggest that the short-term antiproliferative effect of PUFAs may involve PPAR activation in hOB cells, resulting in a cell cycle withdrawal favorable for the long-term differentiating effects of fatty acids. Further studies are now required to confirm the functional role of PPARs in the antiproliferative effects of PUFAs in hOB cells.
Maurin
A C
AC
INSERM Unité 403, Faculté R.T.H. Laënnec, Université Claude Bernard LYON 1, Rue Guillaume Paradin, 69372, Lyon Cedex 08, France.
Chavassieux
P M
PM
Meunier
P J
PJ
D016475:3T3 Cells; D000818:Animals; D016718:Arachidonic Acid / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004281:Docosahexaenoic Acids / Q000494:pharmacology; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000235:genetics / Q000378:metabolism*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
C097240:15-deoxy-delta(12,14)-prostaglandin J2; D007155:Immunologic Factors; D047492:Peroxisome Proliferator-Activated Receptors; D012333:RNA, Messenger; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; C026678:carboprostacyclin; D011464:Epoprostenol; D015230:Prostaglandin D2